Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Completed · Phase 1/Phase 2

Conditions studied: Influenza Immunization

In brief

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Key facts

Study ID

NCT05553301

Run by

Sanofi Pasteur, a Sanofi Company

People needed

560

Starts

2022-10-03

Expected to finish

2024-01-19

Last updated by the study team

2025-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 18 years on the day of inclusion
• A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile OR
• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

You may not qualify if…

• Participants are excluded from the study if any of the following criteria apply:
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• Previous history of myocarditis, pericarditis, and / or myopericarditis
• Self-reported thrombocytopenia, contraindicating Intramuscular vaccination based on Investigator's judgment
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating Intramuscular vaccination based on Investigator's judgment
• Moderate or severe acute illness / infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
• Self-reported or documented seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
• Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration
• NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Peninsula Research Associates Site Number : 8400025 — Rolling Hills Estates, California, United States
• Optimal Research Site Number : 8400059 — San Diego, California, United States
• California Research Foundation Site Number : 8400008 — San Diego, California, United States
• Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400052 — DeLand, Florida, United States
• SIMEDHealth, LLC Site Number : 8400024 — Gainesville, Florida, United States
• Indago Research and Health Center Site Number : 8400014 — Hialeah, Florida, United States
• Cenexel Research Centers of America Site Number : 8400048 — Hollywood, Florida, United States
• Dade Research Center Site Number : 8400011 — Miami, Florida, United States
• Suncoast Research Group, LLC Site Number : 8400038 — Miami, Florida, United States
• Florida International Research Center Site Number : 8400051 — Miami, Florida, United States
• Palm Beach Research Center Site Number : 8400020 — West Palm Beach, Florida, United States
• DM Clinical Research Site Number : 8400032 — Melrose Park, Illinois, United States
• DM Clinical Research - Chicago Site Number : 8400028 — River Forest, Illinois, United States
• Brengle Family Medicine Site Number : 8400005 — Indianapolis, Indiana, United States
• AMR Lexington Site Number : 8400054 — Lexington, Kentucky, United States
• AMR Kansas City Site Number : 8400006 — Kansas City, Missouri, United States
• Velocity Clinical Research Site Number : 8400003 — Omaha, Nebraska, United States
• Coastal Carolina Research Center - N Charleston Site Number : 8400010 — North Charleston, South Carolina, United States
• AMR Knoxville Site Number : 8400046 — Knoxville, Tennessee, United States
• Elligo Health Research Site Number : 8400056 — Austin, Texas, United States
• Sun Research Institute Site Number : 8400030 — San Antonio, Texas, United States
• Clinical Trials of Texas, Inc. Site Number : 8400026 — San Antonio, Texas, United States
• DM Clinical Research - Sugar Land Site Number : 8400031 — Sugar Land, Texas, United States
• Investigational Site Number : 6300003 — Barrio Sabana, Puerto Rico
• Investigational Site Number : 6300002 — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.